112 related articles for article (PubMed ID: 21669040)
21. Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway.
Ferdaoussi M; Abdelli S; Yang JY; Cornu M; Niederhauser G; Favre D; Widmann C; Regazzi R; Thorens B; Waeber G; Abderrahmani A
Diabetes; 2008 May; 57(5):1205-15. PubMed ID: 18252896
[TBL] [Abstract][Full Text] [Related]
22. Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.
Kakimoto T; Kimata H; Iwasaki S; Fukunari A; Utsumi H
J Endocrinol; 2013 Jan; 216(1):13-20. PubMed ID: 23092878
[TBL] [Abstract][Full Text] [Related]
23. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line.
Zhang LW; McMahon Tobin GA; Rouse RL
Toxicol Appl Pharmacol; 2012 Oct; 264(2):274-83. PubMed ID: 22925809
[TBL] [Abstract][Full Text] [Related]
24. IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo.
Choi SE; Choi KM; Yoon IH; Shin JY; Kim JS; Park WY; Han DJ; Kim SC; Ahn C; Kim JY; Hwang ES; Cha CY; Szot GL; Yoon KH; Park CG
Transpl Immunol; 2004; 13(1):43-53. PubMed ID: 15203128
[TBL] [Abstract][Full Text] [Related]
25. Autocrine Interleukin-10 Mediates Glucagon-Like Peptide-1 Receptor-Induced Spinal Microglial β-Endorphin Expression.
Wu HY; Tang XQ; Mao XF; Wang YX
J Neurosci; 2017 Nov; 37(48):11701-11714. PubMed ID: 29084866
[TBL] [Abstract][Full Text] [Related]
26. STAT5 activation by human GH protects insulin-producing cells against interleukin-1beta, interferon-gamma and tumour necrosis factor-alpha-induced apoptosis independent of nitric oxide production.
Jensen J; Galsgaard ED; Karlsen AE; Lee YC; Nielsen JH
J Endocrinol; 2005 Oct; 187(1):25-36. PubMed ID: 16214938
[TBL] [Abstract][Full Text] [Related]
27. Evidence for IL-6 production by and effects on the pancreatic beta-cell.
Campbell IL; Cutri A; Wilson A; Harrison LC
J Immunol; 1989 Aug; 143(4):1188-91. PubMed ID: 2501390
[TBL] [Abstract][Full Text] [Related]
28. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
Gallwitz B
Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
[TBL] [Abstract][Full Text] [Related]
29. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor.
Wu Z; Todorov I; Li L; Bading JR; Li Z; Nair I; Ishiyama K; Colcher D; Conti PE; Fraser SE; Shively JE; Kandeel F
Bioconjug Chem; 2011 Aug; 22(8):1587-94. PubMed ID: 21692471
[TBL] [Abstract][Full Text] [Related]
30. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
31. IFN-γ induced by IL-12 administration prevents diabetes by inhibiting pathogenic IL-17 production in NOD mice.
Zhang J; Huang Z; Sun R; Tian Z; Wei H
J Autoimmun; 2012 Feb; 38(1):20-8. PubMed ID: 22186068
[TBL] [Abstract][Full Text] [Related]
32. Transient beneficial effects of exendin-4 treatment on the function of microencapsulated mouse pancreatic islets.
Bohman S; Waern I; Andersson A; King A
Cell Transplant; 2007; 16(1):15-22. PubMed ID: 17436851
[TBL] [Abstract][Full Text] [Related]
33. Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo.
Uhles S; Wang H; Bénardeau A; Prummer M; Brecheisen M; Sewing S; Tobalina L; Bosco D; Wollheim CB; Migliorini C; Sebokova E
Diabetes Obes Metab; 2011 Apr; 13(4):326-36. PubMed ID: 21205124
[TBL] [Abstract][Full Text] [Related]
34. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
Timmers L; Henriques JP; de Kleijn DP; Devries JH; Kemperman H; Steendijk P; Verlaan CW; Kerver M; Piek JJ; Doevendans PA; Pasterkamp G; Hoefer IE
J Am Coll Cardiol; 2009 Feb; 53(6):501-10. PubMed ID: 19195607
[TBL] [Abstract][Full Text] [Related]
35. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues.
Tews D; Werner U; Eckel J
Horm Metab Res; 2008 Mar; 40(3):172-80. PubMed ID: 18348079
[TBL] [Abstract][Full Text] [Related]
36. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
37. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
38. Antiapoptotic actions of exendin-4 against hypoxia and cytokines are augmented by CREB.
Velmurugan K; Balamurugan AN; Loganathan G; Ahmad A; Hering BJ; Pugazhenthi S
Endocrinology; 2012 Mar; 153(3):1116-28. PubMed ID: 22253425
[TBL] [Abstract][Full Text] [Related]
39. Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages.
Bułdak Ł; Łabuzek K; Bułdak RJ; Machnik G; Bołdys A; Okopień B
Naunyn Schmiedebergs Arch Pharmacol; 2015 Sep; 388(9):905-19. PubMed ID: 25980358
[TBL] [Abstract][Full Text] [Related]
40. The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.
Roy D; Chadwick KD; Tatarkiewicz K; LaCerte C; Bergholm AM; Brodie T; Mangipudy RS; Parkes D; Graziano MJ; Reilly TP
Diabetes Obes Metab; 2014 Oct; 16(10):910-21. PubMed ID: 24666399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
